WO2014140103A3 - Thrombin sensitive coagulation factor x molecules - Google Patents

Thrombin sensitive coagulation factor x molecules Download PDF

Info

Publication number
WO2014140103A3
WO2014140103A3 PCT/EP2014/054841 EP2014054841W WO2014140103A3 WO 2014140103 A3 WO2014140103 A3 WO 2014140103A3 EP 2014054841 W EP2014054841 W EP 2014054841W WO 2014140103 A3 WO2014140103 A3 WO 2014140103A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
coagulation factor
sensitive coagulation
thrombin sensitive
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/054841
Other languages
French (fr)
Other versions
WO2014140103A2 (en
Inventor
Jens Jacob Hansen
Jens Breinholt
Jens Buchardt
Kristoffer WINTHER BALLING
Prafull S. GANDHI
Henrik ØSTERGAARD
Grant E. BLOUSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US14/774,790 priority Critical patent/US20160024487A1/en
Priority to EP14710844.3A priority patent/EP2970933A2/en
Priority to JP2015562126A priority patent/JP2016510984A/en
Priority to CN201480014388.9A priority patent/CN105008530A/en
Publication of WO2014140103A2 publication Critical patent/WO2014140103A2/en
Publication of WO2014140103A3 publication Critical patent/WO2014140103A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX "IVGG" motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia.
PCT/EP2014/054841 2013-03-12 2014-03-12 Thrombin sensitive coagulation factor x molecules Ceased WO2014140103A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/774,790 US20160024487A1 (en) 2013-03-12 2014-03-12 Thrombin sensitive coagulation factor x molecules
EP14710844.3A EP2970933A2 (en) 2013-03-12 2014-03-12 Thrombin sensitive coagulation factor x molecules
JP2015562126A JP2016510984A (en) 2013-03-12 2014-03-12 Thrombin-sensitive coagulation factor X molecule
CN201480014388.9A CN105008530A (en) 2013-03-12 2014-03-12 Thrombin sensitive coagulation factor X molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13158721 2013-03-12
EP13158721.4 2013-03-12
US201361781156P 2013-03-14 2013-03-14
US61/781,156 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014140103A2 WO2014140103A2 (en) 2014-09-18
WO2014140103A3 true WO2014140103A3 (en) 2014-11-06

Family

ID=47843182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/054841 Ceased WO2014140103A2 (en) 2013-03-12 2014-03-12 Thrombin sensitive coagulation factor x molecules

Country Status (5)

Country Link
US (1) US20160024487A1 (en)
EP (1) EP2970933A2 (en)
JP (1) JP2016510984A (en)
CN (1) CN105008530A (en)
WO (1) WO2014140103A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104661685A (en) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） Factor vii conjugates
CA2927756A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
AR101060A1 (en) * 2014-02-12 2016-11-23 Novo Nordisk As FVIII CONJUGATES
AR099328A1 (en) * 2014-02-12 2016-07-13 Novo Nordisk As FACTOR VII CONJUGATES
CN109374902A (en) * 2018-10-08 2019-02-22 杭州康知生物科技有限公司 A kind of latex enhancing Immunoturbidimetric kit of quantitative detection IgG4 and preparation method thereof
WO2020163126A1 (en) * 2019-02-05 2020-08-13 Purdue Research Foundation Method and composition matter for immunoproteasome-mediated delivery into living cells
CN114269937B (en) * 2019-07-03 2026-04-24 帕利昂制药有限公司 Recombinant sialidase and its application
EP3878542A1 (en) * 2020-03-11 2021-09-15 Bayer AG Filter membranes as antifoam level safeguards
CN111569143B (en) * 2020-05-14 2021-05-14 山东省科学院生物研究所 Snake venom prothrombin activator and rapid hemostatic material based on same
CN121736047A (en) * 2026-02-27 2026-03-27 山东艾科达生物科技有限公司 Thrombin fluorogenic substrate for whole blood and its preparation method and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038317A1 (en) * 1997-02-27 1998-09-03 Baxter Aktiengesellschaft Factor x analogues with a modified protease cleavage site
US20060148038A1 (en) * 2002-07-03 2006-07-06 Inst. Nat'l De La Sante Et De La Rech. Medicale Thrombin cleavable factor x analogues
WO2007096116A1 (en) * 2006-02-21 2007-08-30 Csl Behring Gmbh Coagulation factor x polypeptides with modified activation properties
WO2010070137A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038317A1 (en) * 1997-02-27 1998-09-03 Baxter Aktiengesellschaft Factor x analogues with a modified protease cleavage site
US20060148038A1 (en) * 2002-07-03 2006-07-06 Inst. Nat'l De La Sante Et De La Rech. Medicale Thrombin cleavable factor x analogues
WO2007096116A1 (en) * 2006-02-21 2007-08-30 Csl Behring Gmbh Coagulation factor x polypeptides with modified activation properties
WO2010070137A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
WO2014140103A2 (en) 2014-09-18
JP2016510984A (en) 2016-04-14
US20160024487A1 (en) 2016-01-28
EP2970933A2 (en) 2016-01-20
CN105008530A (en) 2015-10-28

Similar Documents

Publication Publication Date Title
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
IL294314A (en) Fibronectin based scaffold domain proteins that bind to myostatin
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
EA201590910A1 (en) PROTEINS BASED ON A STRUCTURAL FIBRONECTIN DOMAIN, CONNECTING PCSK9
CA2905972C (en) Gla domains as targeting agents
HK1221725A1 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
BR112016004095A2 (en) administration of quinurenine depletion enzymes for tumor therapy
EA201691235A1 (en) MODIFIED SERPINS FOR THE TREATMENT OF BLOOD COVERAGE DISORDERS
BR112014003109A2 (en) plasminogen and plasmin variants
EP4488289A3 (en) Long-acting coagulation factors and uses thereof
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
MX361647B (en) Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications.
BR112013021661A2 (en) objectification of tlt-1 coagulation factor on activated platelets
WO2013106689A8 (en) Hcv ns3 protease inhibitors
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.
GB201118201D0 (en) Novel peptides
CY1115961T1 (en) ORVEPITANT MALEATE ANHYDRATED FORM OF CRYSTAL MALINE
NZ602380A (en) Peptides for vaccine against birch allergy
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
MX2015012720A (en) Base addition salts of nitroxoline and uses thereof.
MX380585B (en) SHORT-ACTING FACTOR VII POLYPEPTIDES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710844

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2014710844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014710844

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015562126

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14774790

Country of ref document: US